Black Rock Inc. T Scan Therapeutics, Inc. Put Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$16.3 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$10.9 Million0.3% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$5.79 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.47 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$4.34 Million3.67% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $39.4M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...